Finance
Novo Nordisk Launches Higher-Dose Wegovy in the United States
Published by Global Banking & Finance Review®
Posted on April 7, 2026
2 min readLast updated: April 7, 2026
Add as preferred source on GoogleQuick Summary
Novo Nordisk has made the FDA‑approved 7.2 mg “Wegovy HD” (higher‑dose semaglutide) available across U.S. pharmacies, telehealth providers and NovoCare; cash‑pay adults face about $399/month, while insured patients may pay $25/month with savings.
Novo Nordisk launches higher-dose Wegovy in the United States
Overview of Wegovy HD Launch and Market Impact
Introduction to Wegovy HD Availability
April 7 (Reuters) - Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.
FDA Approval and Dosage Details
Regulatory Approval
The 7.2-milligram dose, branded as Wegovy HD, gained approval under the FDA Commissioner's National Priority Review Voucher program last month.
Comparison to Previous Dosage
Before the approval, the highest authorized dose of the injectable Wegovy for weight loss was 2.4 mg.
Distribution and Accessibility
Pharmacy and Telehealth Availability
The company said the higher-dose Wegovy will be available through U.S. pharmacies, NovoCare Pharmacy and select telehealth providers.
Pricing and Subscription Plans
Cost for Patients
Cash-paying adults prescribed Wegovy HD can expect to pay $399 per month, while commercially insured patients may pay as little as $25 per month using the Wegovy savings offer, Novo said.
Future Discounted Subscription Plan
Strategy Against Market Competition
Last month, Novo said it plans to launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering steep discounts to regain ground ceded to Eli Lilly in the obesity-drug market.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Key Takeaways
- •Wegovy HD (7.2 mg) was approved via FDA’s expedited National Priority Review Voucher program in March and hit U.S. market in April 2026
- •Clinical data show a ~20–21% average body‑weight loss compared to ~16% at the 2.4 mg dose, though higher side‑effect rates of GI issues and skin sensations were noted
- •Novo Nordisk’s subscription program launched March 31, 2026, allows self‑pay patients to save up to $1,200/year once Wegovy HD is included
Frequently Asked Questions about Novo Nordisk launches higher-dose Wegovy in the United States
1What is the new dose of Wegovy launched by Novo Nordisk?
Novo Nordisk has launched a 7.2-milligram higher-dose version of Wegovy, branded as Wegovy HD.
2Where is the higher-dose Wegovy available?
Wegovy HD is available across the United States through U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers.
3How much does Wegovy HD cost for patients?
Cash-paying adults can expect to pay $399 per month, while commercially insured patients may pay as little as $25 monthly with the Wegovy savings offer.
4What recent approval did Wegovy HD receive?
Wegovy HD gained FDA approval under the National Priority Review Voucher program in the previous month.
5Will there be discounts or subscription plans for Wegovy HD?
Novo Nordisk plans to launch a discounted subscription plan for U.S. patients paying for Wegovy HD themselves.
